APPROVED_FOR_MARKETINGNot Applicable

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

United States

Plain-language summary

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

NCT IDNCT01825395

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeEXPANDED_ACCESS